All posts by CAC2

CAC2 Childhood Cancer Community News Digest (September 19-25)

Assorted News from the Last Week: The FDA has approved sodium thiosulfate (Pedmark) to reduce the risk of ototoxicity associated with cisplatin in pediatric patients aged 1 month and older with localized, nonmetastatic solid tumors. The White House announced its support for the Childhood Cancer STAR Reauthorization Act. Answers to common questions about COVID-19 vaccines in children with cancer Cancer in kids tied to prenatal exposure to high-dose folic acid and seizure meds, but no link seen among children of mothers without epilepsy. Scientists have found that group 3 and 4 medulloblastoma arise from the rhombic lip, knowledge that may […]

Read more

CAC2 Childhood Cancer Community News Digest (September 12-18)

Assorted News from the Last Week: Supporting Children and Families Through a Cancer Diagnosis by Child Life Specialist Nicolle Bengtson. Nearly 20 years since her initial diagnosis, CAC2 Member Juanita Prada now works with children who are fighting cancer just like she did. Day One Biopharmaceuticals emerged in May to develop new drugs specifically for children with cancer. Now, as it ramps up its work, the company is making a flurry of new hires and new board appointments, including a new CEO: Jeremy Bender, Ph.D., who previously led corporate development at Gilead Sciences. Challenges burden pediatric oncologists following the peak […]

Read more

CAC2 Childhood Cancer Community News Digest (August 29-September 11)

Assorted News from the Last Two Weeks: National Cancer Institute’s CCDI Molecular Characterization Initiative adds rare tumors. Study provides first in-depth look at major mix-ups in the genomic terrain of pediatric high-grade gliomas. LLS is working to change the pediatric clinical trial model. The aftermath of childhood cancer:  2000 days without Ana Biden appoints former government scientist as first leader of ARPA-H. The use of tisagenlecleucel (Kymriah) in children younger than 3 years of age with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL) was as effective, and safe, in a retrospective cohort study as it was previously seen to […]

Read more

Guest Blog–National Cancer Institute’s CCDI Molecular Characterization Initiative Adds Rare Tumors

Children, adolescents, and young adults (AYAs) with newly diagnosed rare tumors are now eligible to enroll in the CCDI Molecular Characterization Initiative. Rare tumors are childhood cancers that have a low number of patients, which have been hard to study and understand. Potential participants must also be receiving care from a Children’s Oncology Group-affiliated hospital. Enrollment is still also open to children and AYAs with central nervous system tumors and soft tissue sarcomas. The initiative will continue to expand to children and AYAs outside of Children’s Oncology Group–affiliated hospitals, those with other childhood cancers, and those whose cancer has returned. […]

Read more

CAC2 Childhood Cancer Community News Digest (15-28)

Assorted News from the Last Two Weeks: The Food and Drug Administration (FDA) approved Imbruvica (ibrutinib) for the treatment of children aged 1 year or older with chronic graft-versus-host disease (cGVHD) after one or more lines of systemic therapy, according to a news release from the agency. FDA drug approvals, pediatrics — 2022 midyear review Guidebook for caregivers of children with rare and/or serious illnesses 10 gifts to give a friend whose child has cancer or another serious illness Researchers identified a metabolic vulnerability in neuroblastoma that could be exploited to overturn these tumors’ resistance to therapy. Millions of Americans, […]

Read more

CAC2 Childhood Cancer Community News Digest (August 8-14)

Assorted News from the Last Week: Leukemia and Lymphoma Society’s (LLS) has launched its Dare to Dream Project as an extension of itself Children’s Initiative.  It will expand education and support services for patients and families, drives advocacy and policy efforts, and increases investments in childhood blood cancer research. Neuroblastoma cells have an extreme need for amino acids. Scientists at the Hopp Children’s Cancer Center Heidelberg (KiTZ), the German Cancer Research Center (DKFZ), the University of Heidelberg, and HI-STEM gGmbH have now discovered the molecular mechanisms underlying this and how the cancer cells could be turned off. From the Washington […]

Read more

Guest Blog–National Cancer Institute Launches the CCDI Molecular Targets Platform

The Molecular Targets Platform is an NCI-supported instance of the  Open Targets Platform with a focus on preclinical pediatric oncology data. It is a tool that supports the identification and prioritization of molecular targets expressed in childhood cancers.   The Molecular Targets Platform builds upon the data and functionality of the Open Targets Platform while also including: The FDA Pediatric Molecular Target Lists (FDA PMTL) Analyses of pediatric oncology datasets from the Open Pediatric Cancer (OpenPedCan) project at the Children’s Hospital of Philadelphia: Therapeutically Applicable Research to Generate Effective Treatments (TARGET) Open Pediatric Brain Tumor Atlas (OpenPBTA) Gabriella Miller Kids […]

Read more

CAC2 Childhood Cancer Community News Digest (July 25- August 7)

Assorted News from the Last Two Weeks: The CCDI Molecular Targets Platform is the National Cancer Institute’s instance of the Open Targets Platform, specific to childhood cancers which will allow researchers to find data from multiple sources on molecular targets—molecules involved in the growth and spread of cancer cells. Identifying these targets, how they affect cancers, and how they interact with drugs can help improve how childhood cancers are treated. To explore the Molecular Targets Platform, visit: moleculartargets.ccdi.cancer.gov. From the Washington Post:  Pushed by parent activists and buoyed by new funding, scientists explore novel strategies to treat deadly pediatric cancers. […]

Read more

Community News: Update on Federal Childhood Cancer Appropriations Process

Update from our colleagues at the Alliance for Childhood Cancer (July 28, 2022): The Senate Appropriations Committee included language to fund the Childhood Cancer STAR Act and the Childhood Cancer Data Initiative fully again this year in its Fiscal Year 2023 Labor-HHS Appropriations bill.  In addition, the FY23 Defense Appropriations bill included many topics related to childhood and AYA cancer research and maintained level funding at $130 million for the Peer Reviewed Cancer Research Program. This step is important to our requests being included in the final appropriations package when Congress considers the next budget. Here are some key sections [...] Read more

CAC2 Childhood Cancer Community News Digest (July 18-24)

Assorted News from Last Week: The Biden administration has selected Monica Bertagnolli, a renowned surgical oncologist, as the next director of the National Cancer Institute. (gated) The Pediatric Oncology Group of Ontario issued its latest report on childhood cancer efforts in Ontario. Bringing next-generation CAR T-cell therapies to children with solid cancers The Food and Drug Administration (FDA) recently approved the combination of the targeted drugs dabrafenib (Tafinlar)and trametinib (Mekinist) for the treatment of people with nearly any type of advanced solid tumor that has a specific mutation in a gene called BRAF. Results were reported from a phase I safety […]

Read more